FDA’s Ganley Puts Rx Switch Studies In “Real World” Context
This article was originally published in The Tan Sheet
Accurate extrapolation of actual-use data into broader consumer settings will be a defining measure of success for switching chronic disease drugs in the future, according to FDA Office of Nonprescription Products Director Charles Ganley, MD
You may also be interested in...
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says
A joint FDA advisory committee meeting evaluating the Rx-to-OTC switch prospects of topical corticosteroids underscored the different approaches to switches taken by OTC drug advisors and more cautious prescribers with category-specific expertise
A joint FDA advisory committee review of J&J/Merck's nonprescription Mevacor Daily centered in part on long-term consumer compliance with the indicated cholesterol-lowering regimen